Inhibition of cyclooxygenase: A novel approach to cancer prevention

Proceedings of the Society for Experimental Biology and Medicine

Volumn 216, Issue 2, 1997, Pages 201-210

  Subbaramaiah, Kotha ^a,b   Zakim, David ^a   Weksler, Babette B ^a   Dannenberg, Andrew J ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b STRANG CANCER PREVENTION CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NAPHTHYLAMINE; AROMATIC AMINE; AROMATIC HYDROCARBON; BENZIDINE DERIVATIVE; CARCINOGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE;

APOPTOSIS; ARACHIDONIC ACID METABOLISM; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; ENZYME INHIBITION; ENZYME REGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; XENOBIOTIC METABOLISM;

EID: 0030847426     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-216-44170     Document Type: Review

References (135)

1. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, ZebrO T. Prostaglandins and breast cancer. Lancet 2:624-626, 1977.
2. Bennett A. The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res 25:539-542, 1986.
3. Bennett A, Carroll MA, Stamford IF, Whimster WF, Williams F. Prostaglandins and human lung carcinomas. Br J Cancer 46:888-893, 1982.
4. Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 28:315-318, 1987.
5. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518-523, 1993.
6. Vanderveen EE, Grekin RC, Swanson NA. Arachidonic acid metabolites in cutaneous carcinoma. Arch Dermatol 122:407-412, 1986.
7. Bennett A, Carter L, Stamford IF. Prostaglandin-like material extracted from squamous carcinomas of the head and neck. Br J Cancer 41:204-208, 1980.
8. Jung TTK, Berlinger NT, Juhn SK. Prostaglandins in squamous cell carcinoma of the head and neck: A preliminary study. Laryngoscope 95:307-312, 1985.
9. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 54:83-94, 1996.
10. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 47:5340-5346, 1987.
11. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52:5575-5589, 1992.
12. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55:1464-1472, 1995.
13. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560, 1996.
14. Giardiello FM, Hamilton SR, Krush AJ, Piantodosi S, Hylind LM, Celano P, Booker SV, Robinson RC, Offerhaus GJA. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993.
15. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991.
16. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241-246, 1994.
17. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE. Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614, 1995.
18. McCormick DL, Moon RC. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. Br J Cancer 48:859-861, 1983.
19. McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 45:1803-1808, 1985.
20. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138-146, 1994.
21. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7:203-205, 1996.
22. Perkins TM, Shklar G. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral Surg 53:170-178, 1982.
23. Cornwall H, Odukoya O, Shklar G. Oral mucosal tumor inhibition by ibuprofen. Oral Maxillofac Surg 41:795-800, 1983.
24. Funkhouser EM, Sharp PH. Aspirin and reduced risk of esophageal carcinoma. Cancer 76:1116-1119, 1995.
25. Castonguay A, Rioux N. Inhibition of lung tumorigenesis by sulindac: Comparison of two experimental protocols. Carcinogenesis 18:491-496, 1997.
26. Kujubu DA, Fletcher BS, Vamum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866-12872, 1991.
27. O'Banion MK, Sadowsky HB, Winn V, Young DA. A serum and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygense-related protein. J Biol Chem 266:23261-23267, 1991.
28. DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor and phorbol ester. J Clin Invest 93:493-498, 1994.
29. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 268:9049-9054, 1993.
30. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB. Arterioscler Thromb 14:1021-1031, 1994.
31. Xie W, Herschman HR. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 270:27622-27628, 1995.
32. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56:4424-4429, 1996.
33. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 93:4816-4820, 1996.
34. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1994.
35. Kargman SL, O'Neil GP, Vickers PJ, Evans JF, Mancini JA, Jothy JA. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55:2556-2559, 1995.
36. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55:3785-3789, 1995.
37. Δ716 knockout mice by inhibition of cyclooxygenase-2 (Cox-2). Cell 87:803-809, 1996.
38. Wahle KW. Dietary regulation of essential fatty acid metabolism and membrane phospholipid composition. Biochem Soc Trans 18:775-778, 1990.
39. Eberhart CE, DuBois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 109:285-301, 1995.
40. 2 and signal transduction. J Am Soc Nephrol 3:128-150, 1992.
41. Capdevila JH, Falck JR, Estabrook RW. Cytochrome P450 and the arachidonate cascade. FASEB J 6:731-736, 1992.
42. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237:1171-1176, 1987.
43. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 49:153-179, 1991.
44. Basu AK, Marnett LJ. Unequivocal demonstration that malondialdehyde is a mutagen. Carcinogenesis 4:331-333, 1983.
45. Basu AK, O'Hara SM, Valladier P, Stone K, Mols O, Marnett LJ. Identification of adducts formed by reaction of guanine nucleosides with malondialdehyde and structurally related aldehydes. Chem Res Toxicol 1:53-59, 1988.
46. Gusovsky F. Prostaglandin receptors in NIH 3T3 cells: Coupling of one receptor to adenylate cyclase and of a second receptor to phospholipase C. Mol Pharmacol 40:633-638, 1991.
47. 1. Molecular mechanisms and therapeutic utility. Prog Hemost Thromb 10:307-337, 1991.
48. 2: Its generation and role in platelet activation. Prog Lipid Res 28:273-301, 1989.
49. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 114:307-319, 1991.
50. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 33:435-465, 1993.
51. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 15:179-194, 1995.
52. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57:1276-1280, 1997.
53. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10:503-507, 1997.
54. Williams CW, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111:1134-1140, 1996.
55. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566-4569, 1996.
56. Tiano H, Chulada P, Spalding J, Lee C, Loftin C, Mahler J, Morham S, Langenbach R. Effects of cyclooxygenase deficiency on inflammation and papilloma development in mouse skin. Proc Am Assoc Cancer Res 38:1727, 1997.
57. Yokoyama C, Tanabe T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 165:888-894, 1989.
58. DeWitt DL, El-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, Smith WL. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 265:5192-5198, 1990.
59. Feng L, Sun W, Xia Y, Tang WW, Chanmugam P, Soyoola E, Wilson CB, Hwang D. Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression. Arch Biochem Biophys 307:361-368, 1993.
60. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 263:3550-3553, 1988.
61. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85:1412-1416, 1988.
62. Simmons DL, Levy DB, Yannoni Y, Erikson RL. Identification of a phorbol ester-repressible v-src inducible gene. Proc Natl Acad Sci USA 86:1178-1182, 1989.
63. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89:7384-7388, 1992.
64. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 89:4888-4892, 1992.
65. Kennedy BP, Chan CC, Culp SA, Cromlish WA. Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem Biophys Res Commun 197:494-500, 1993.
66. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692-2696, 1991.
67. Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 5:2304-2312, 1991.
68. Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, Takahashi E, Tanabe T. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 221:889-897, 1994.
69. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 267:4334-4338, 1992.
70. Xie W, Merrill JR, Bradshaw WS, Simmons DL. Structural determination and promoter analysis of the chicken mitogen-inducible prostaglandin G/H synthase gene and genetic mapping of the murine homologue. Arch Biochem Biophys 300:247-252, 1993.
71. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: Why two isoforms? Am J Physiol 270:G393-G400, 1996.
72. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46:659-667, 1986.
73. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysacchardie and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 270:24965-24971, 1995.
74. Otto JC, DeWitt DL, Smith WL. N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem 268:18234-18242, 1993.
75. Habib A, Creminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of cyclooxygenase-2. J Biol Chem 268:23448-23454, 1993.
76. 2 synthase-1. Nature 367:243-249, 1994.
77. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nature Structural Biology 3:927-933, 1996.
78. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648, 1996.
79. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, Smith WL. Different intracellular locations for prostaglandin H synthase-1 and -2. J Biol Chem 270:10902-10908, 1995.
80. Chulada PC, Loftin CD, Winn VD, Young DA, Tiano HF, Eling TE, Langenbach R. Relative activities of retrovirally expressed murine prostaglandin synthase-1 and -2 depend on source of arachidonic acid. Arch Biochem Biophys 330:301-313, 1996.
81. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483-492, 1995.
82. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, Trzaskos JM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378:406-409, 1995.
83. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473-482, 1995.
84. Marnett LJ, Wlodawer P, Samuelsson B. Co-oxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland. J Biol Chem 250:8510-8517, 1975.
85. Eling TE, Thompson DC, Foureman GL, Curtis JF, Hughes MF. Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 30:1-45, 1990.
86. Eling TE, Curtis JF. Xenobiotic metabolism by prostaglandin H synthase. Pharmacol Ther 53:261-273, 1992.
87. Marnett LJ, Reed GA, Dennison DJ. Prostaglandin synthetase dependent activation of 7,8-dihydro-7,8-dihydroxy-benzo[a]pyrene to mutagenic derivatives. Biochem Biophys Res Commun 82:210-216, 1978.
88. Guthrie J, Robertson IGC, Zeiger E, Boyd JA, Eling T. Selective activation of some dihydrodiols of several polycyclic aromatic hydrocarbons to mutagenic products by prostaglandin synthetase. Cancer Res 42:1620-1623, 1982.
89. Denissenko MF, Pao A, Tang M-S, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274:430-432, 1996.
90. Kadlubar FF, Frederick CB, Weis CC, Zenser TV. Prostaglandin endoperoxide synthetase-mediated metabolism of carcinogenic aromatic amines and their binding to DNA and protein. Biochem Biophys Res Commun 108:253-258, 1982.
91. Case RAM, Hosker MW, McDonald DB, Pearson JT. Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Br J Ind Med 11:75-104, 1954.
92. Hu Z, Wells PG. In vitro and in vivo biotransformation and covalent binding of benzo[a]pyrene in Gunn and RHA rats with genetic deficiency in bilirubin uridine diphosphate-glucuronosyltransferase. J Pharmacol Exp Ther 263:334-342, 1992.
93. Levine L. Chemical carcinogens stimulate canine kidney (MDCK) cells to produce prostaglandins. Nature 268:447-448, 1977.
94. Hassad A, Levine L. Induction of fatty acid cyclooxygenase activity in canine kidney cells (MDCK) by benzo[a]pyrene. J Biol Chem 252:6591-6593, 1977.
95. Kraemer SA, Arthur KA, Denison MS, Smith WL, DeWitt DL. Regulation of prostaglandin endoperoxidase H synthase-2 expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Arch Biochem Biophys 330:319-328, 1996.
96. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Ramonetti JT, Dannenberg AJ. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 18:795-799, 1997.
97. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83:493-501, 1995.
98. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336-3340, 1997.
99. Weitzman SA, Gordon LI. Inflammation and cancer: Role of phagocyte-generated oxidants in carcinogenesis. Blood 76:655-663, 1990.
100. Plescia OJ, Smith AH, Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 72:1848-1851, 1975.
101. Baich CM, Doghert PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery 95:71-77, 1984.
102. Goodwin JS, Ceuppens JL. Regulation of immune response by prostaglandins. J Clin Immunol 3:295-315, 1983.
103. Goodwin JS, Bankhurst AD, Messner RP. Suppression of human T-cell mitogenesis by prostaglandin; Existence of a prostaglandin producing suppressor cell. J Exp Med 146:1719-1734, 1977.
104. Brunda MJ, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 124:2682-2688, 1980.
105. Taffet SM, Russell SW. Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J Immunol 126:424-427, 1980.
106. Baker PE, Fahey JV, Munck A. Prostaglandin inhibition of T-cell proliferation is mediated at two levels. Cell Immunol 61:52-61, 1981.
107. 2. Biochem Biophys Res Commun 137:404-410, 1986.
108. 2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 154:3383-3390, 1995.
109. Grinwich KD, Plescia OJ. Tumor-mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis. Prostaglandins 14:1175-1183, 1977.
110. Tilden AB, Balch CM. Indomethacin enhancement of immunocompetence in melanoma patients. Surgery 90:77-84, 1981.
111. Han T, Takita H. Indomethacin-mediated enhancement of lymphocyte response to mitogens in healthy subjects and lung cancer patients. Cancer 46:2416-2420, 1980.
112. Huang M-T, Lou Y-R, Ma W, Newmark HL, Reuhl KR, Conney AH. Inhibitory effects of dietary curcumin on forestomach, duodenal and colon carcinogenesis in mice. Cancer Res 54:5841-5847, 1994.
113. Lu X, Xie W, Reed D, Bradshaw WS, Simmons DL. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 92:7961-7965, 1995.
114. Pasticha PJ, Bedi A, O'Connor K, Rashid A, Akhtar AJ, Zahurak ML, Piantadosi S, Hamilton SR, Giardiello FM. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109:994-998, 1995.
115. Duggan JM, Dobson AJ, Johnson H, Rahey P. Peptic ulcer and nonsteroidal anti-inflammatory agents. Gut 27:929-933, 1986.
116. Reitz DB, Li JJ, Norton MB, Reinhard EJ, Collins JT, Anderson GD, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Isakson PC. Selective cyclooxygenase inhibitors: Novel 1,2-diarylcyclopentenes are potent and orally active Cox-2 inhibitors. J Med Chem 37:3878-3881, 1984.
117. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1299:125-140, 1996.
118. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of Cox-2 specific inhibitors. J Biol Chem 271:15810-15814, 1996.
119. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228-3232, 1994.
120. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013-12017, 1994.
121. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47:55-59, 1994.
122. Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 32:126-130, 1997.
123. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99:2254-2259, 1997.
124. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. Characterization of protein tyrosine kinases from human breast cancer: involvement of c-src oncogene product. Cancer Res 52:4773-4778, 1992.
125. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 267:1782-1788, 1995.
126. Chanmugam P, Feng L, Liou S, Jang BC, Boudreau M, Yu G, Lee JH, Kwon HJ, Beppu T, Yoshida M, Xia Y, Wilson CB, Hwang D. Radicicol, a potent tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis. J Biol Chem 270:5418-5426, 1995.
127. Blanco A, Habib A, Levy-Toledano S, Maclouf J. Involvement of tyrosine kinases in the induction of cyclooxygenase-2 in human epithelial cells. Biochem J 312:419-423, 1995.
128. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res 57:1081-1085, 1997.
129. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486, 1995.
130. Huang T-S, Lee S-C, Lin J-K. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 88:5292-5296, 1991.
131. Kelley DJ, Sacks PG, Ramonetti JT, Schantz SP, Dannenberg AJ. Curcumin inhibits prostaglandin synthesis and cyclooxygenase-2 expression in oral epithelial cells. Proc Am Assoc Cancer Res 37:909, 1996.
132. Moon RC, McCormick DL, Mehta RG. Inhibition of carcinogenesis by retinoids. Cancer Res 43:24693-24753, 1983.
133. Schule R, Rangarajan P, Yang N, Kliewer S, Ransone LJ, Bolado J, Verma IM, Evans RM. Retinoic acid is a negative regulator of AP-1 responsive genes. Proc Natl Acad Sci USA 88:6092-6096, 1991.
134. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 57:2890-2895, 1997.
135. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu X-P, Pfahl M. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372:107-111, 1994.